Loading
NASDAQHealthcareBiotechnology
Latest quote
$36.90
+$2.72 · +7.96%
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Previous close
$36.90
+$2.72 · +7.96%
After-hours
$37.7901
+$0.8901 · +2.41%
Oct 9, 7:55 PM ET
Regular session · ET · Market data may be delayed.
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Day range
Current $36.90
52-week range
Current $36.90
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
32
Expensive
Sentiment
51
Mixed
Risk
51
Elevated Risk
Momentum
64
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Day range
Current $36.90
52-week range
Current $36.90
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 29, 2022 | 1:15 | — | — |
Stock split | Mar 3, 2020 | 1:8 | — | — |
Effective Aug 29, 2022
1:15
Effective Mar 3, 2020
1:8
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM112.71M0.14%78.27B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF59.85M0.06%95.4B USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO39.51M0.29%13.97B USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB33.96M0.32%10.28B USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO29.71M0.16%18B USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA24.4M0.11%21.73B USD0.03%$32.79+0.40%
iShares U.S. Pharmaceuticals ETFIHE15.99M1.04%1.52B USD0.37%$100.09+1.24%
Fidelity Enhanced Small Cap ETFFESM14.73M0.22%6.41B USD0.28%$45.46+0.46%iShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares U.S. Pharmaceuticals ETFIHEFidelity Enhanced Small Cap ETFFESMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
